{"id":462,"date":"2026-09-06T20:55:22","date_gmt":"2026-09-06T20:55:22","guid":{"rendered":"https:\/\/premiumpeptide.shop\/research\/compounds\/"},"modified":"2026-09-07T00:46:04","modified_gmt":"2026-09-07T00:46:04","slug":"compounds","status":"publish","type":"page","link":"https:\/\/premiumpeptide.shop\/en\/research\/compounds\/","title":{"rendered":"Research Compound Library"},"content":{"rendered":"

The Research Compound Library brings together structured reference information on compounds used in laboratory and research contexts. It covers general data such as designation, synonyms, structural features, molecular mass and the usual analytical characterisation. The entries contain no medical or therapeutic information, no dosages and no application instructions.<\/p>\n

Each entry links to the corresponding catalogue products and to the matching analytical resources in the Research section<\/a>. The library is being expanded step by step; the following entries are currently available.<\/p>\n

Compound overview<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Compound<\/th>\nClassification<\/th>\nAnalytical focus<\/th>\n<\/tr>\n<\/thead>\n
BPC-157<\/a><\/td>\nSynthetic pentadecapeptide (15 amino acids)<\/td>\nRP-HPLC without 280 nm detection, mass confirmation around 1,419 Da<\/td>\n<\/tr>\n
TB-500<\/a><\/td>\nTrade designation for thymosin beta-4 or its actin-binding fragment<\/td>\nVariant clarification via the molecular mass (approximately 4.9 kDa versus approximately 0.9 kDa)<\/td>\n<\/tr>\n
GHK-Cu<\/a><\/td>\nCopper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine<\/td>\nSeparate determination of peptide fraction and metal content<\/td>\n<\/tr>\n
CJC-1295<\/a><\/td>\nGRF(1-29) analogue, with and without DAC linker<\/td>\nDifferentiation of the two variants by mass (approximately 3,368 versus approximately 3,647 Da)<\/td>\n<\/tr>\n
Ipamorelin<\/a><\/td>\nPentapeptide with non-proteinogenic building blocks and C-terminal amidation<\/td>\nLimits of HPLC and MS with D-configured amino acids<\/td>\n<\/tr>\n
Semaglutide<\/a><\/td>\nAcylated peptide analogue of 31 amino acids with a C18 diacid side chain<\/td>\nGradient requirements for lipopeptide conjugates<\/td>\n<\/tr>\n
Tirzepatide<\/a><\/td>\nAcylated peptide analogue of 39 amino acids, dual receptor profile<\/td>\nDifferentiation from structurally related analogues<\/td>\n<\/tr>\n
Retatrutide<\/a><\/td>\nAcylated peptide analogue of 39 amino acids, described in the literature as a triple agonist<\/td>\nAnalysis of a single substance versus a combination product<\/td>\n<\/tr>\n
Semax<\/a><\/td>\nHeptapeptide composed of ACTH(4-7) and Pro-Gly-Pro<\/td>\nMethionine oxidation as a quality marker (plus 16 Da)<\/td>\n<\/tr>\n
Selank<\/a><\/td>\nHeptapeptide composed of tuftsin and Pro-Gly-Pro, strongly basic<\/td>\nEarly elution of polar peptides, detection only at 214 to 220 nm<\/td>\n<\/tr>\n
Sermorelin<\/a><\/td>\nSynthetisches GHRH-Analogon (1-29) mit amidiertem C-Terminus<\/td>\nRP-HPLC mit 280-nm-Option \u00fcber Tyrosin, Massenbest\u00e4tigung um 3.358 Da<\/td>\n<\/tr>\n
Tesamorelin<\/a><\/td>\nN-terminal acyliertes GHRH-Analogon aus 44 Aminos\u00e4uren<\/td>\nNachweis der Acylgruppe \u00fcber die dekonvolutierte Masse um 5.136 Da<\/td>\n<\/tr>\n
GHRP-2<\/a><\/td>\nSynthetisches Hexapeptid mit D-Aminos\u00e4uren und C-terminalem Amid<\/td>\nMassenbest\u00e4tigung um 818 Da, Amidform gegen freie S\u00e4ureform<\/td>\n<\/tr>\n
GHRP-6<\/a><\/td>\nSynthetisches Hexapeptid mit D-Aminos\u00e4uren und C-terminalem Amid<\/td>\nZwei Tryptophanreste erlauben zus\u00e4tzliche 280-nm-Detektion, Masse um 873 Da<\/td>\n<\/tr>\n
AOD-9604<\/a><\/td>\nModifiziertes hGH-Fragment mit intramolekularer Disulfidbr\u00fccke<\/td>\nDisulfidzustand und Massenbest\u00e4tigung um 1.815 Da<\/td>\n<\/tr>\n
Epithalon<\/a><\/td>\nSynthetisches Tetrapeptid (AEDG)<\/td>\nSehr polar, keine 280-nm-Detektion, Massenbest\u00e4tigung um 390 Da<\/td>\n<\/tr>\n
MOTS-c<\/a><\/td>\nMitochondrial kodiertes Peptid aus 16 Aminos\u00e4uren<\/td>\nMethioninoxidation als Nebenpeak, Massenbest\u00e4tigung um 2.175 Da<\/td>\n<\/tr>\n
Thymosin Alpha-1<\/a><\/td>\nAcetyliertes Polypeptid aus 28 Aminos\u00e4uren<\/td>\nAcetylierungsstatus nur \u00fcber die Masse belegbar, um 3.108 Da<\/td>\n<\/tr>\n
KPV<\/a><\/td>\nTripeptid (Lysin-Prolin-Valin), C-terminales \u03b1-MSH-Fragment<\/td>\nKurzkettige Sequenz ohne 280-nm-Chromophor, Massenbest\u00e4tigung um 342 Da<\/td>\n<\/tr>\n
Cagrilintid<\/a><\/td>\nAcyliertes Amylin-Analogon aus 32 Aminos\u00e4uren<\/td>\nAcylierungsgrad und Sequenznebenprodukte massenspektrometrisch abzugrenzen, um 3.750 Da<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Structure of the entries<\/h2>\n

Every compound entry follows the same structure: structural description, research context, analytical identification, interpretation of purity figures, requirements for documentation and batch assignment, and notes on the storage of laboratory substances. Each entry is supplemented by the corresponding catalogue products.<\/p>\n

Products with different quantities or dosage forms of the same compound are combined into a single entry. Combination products appear under each compound they contain.<\/p>\n

Further resources<\/h2>\n